[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352346-105":59,"doc-detail-352346-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bone-mineral-density-as-a-prognostic-marker-in-patients-with-non-small-cell-lung-cancer-undergoing-neoadjuvant-chemoimmunotherapy","Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy","","Non-small cell lung cancer (NSCLC) remains the most prevalent lung cancer, and surgery is the primary curative approach; yet recurrence is common. Neoadjuvant chemoimmunotherapy (NICT) improves outcomes, but heterogeneous responses create an urgent need for reliable prognostic biomarkers. This study evaluates whether computed tomography (CT)-derived bone mineral density (BMD) predicts disease-free survival (DFS) and overall survival (OS) in NSCLC patients receiving NICT.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bone-mineral-density-as-a-prognostic-marker-in-patients-with-non-small-cell-lung-cancer-undergoing-neoadjuvant-chemoimmunotherapy/352346/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bone-mineral-density-as-a-prognostic-marker-in-patients-with-non-small-cell-lung-cancer-undergoing-neoadjuvant-chemoimmunotherapy/352346.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study on bone mineral density in NSCLC?","Question",{"text":112,"@type":113},"To determine whether CT-derived bone mineral density (BMD) predicts prognosis, particularly disease-free survival (DFS), in NSCLC patients undergoing neoadjuvant chemoimmunotherapy (NICT).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BMD measured and which vertebrae were assessed?",{"text":117,"@type":113},"Baseline and preoperative BMD were analyzed from chest CT for T10, T12, and L1 vertebrae, with CT described as highly correlated with dual-energy X-ray absorptiometry (DXA).",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key prognostic findings for L1 BMD?",{"text":121,"@type":113},"Higher baseline and preoperative L1 BMD were associated with significantly improved DFS, and both measures were concluded to be valuable independent prognostic biomarkers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352346,1790185714,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Zhou et al. World Journal of Surgical Oncology (2026) 24:69  \n[https://doi.org/10.1186/s12957-025-04186-2](https://doi.org/10.1186/s12957-025-04186-2)  \nWorld Journal of Surgical Oncology  \nRESEARCH Open Access  \nBone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy  \nFengyi Zhou1,2†, Peile Li1,2†, Ji’an Zou1,2, Weixuan Lei1,2, Wei Han1,2, Yun Gu1,2, Yan Hu1,2, Chao Zeng1,2, Jina Li 1,2, Jieming Cao1,2, Quanming Fei1,2, Mengqi Shao1,2, Junqi Yi1,2, Zeyu Cheng1,2, Li Wang1,2, Yazhuo Liu3* and Wenliang Liu 1,2*  \nAbstract  \nBackground Non-small cell lung cancer (NSCLC) is the most common lung cancer, and surgery is the primary curative treatment approach. Recently, neoadjuvant immunotherapy combined with chemotherapy (NICT) has become an important strategy. However, not all patients benefit, underscoring the need for reliable prognostic biomarkers. Bone mineral density (BMD) is associated with the prognosis of various cancers. This study explores the relationship between computed tomography (CT)-derived BMD and prognosis in NSCLC patients treated with NICT. Methods 101 stage IIA-IIIB NSCLC patients undergoing NICT and R0 resection surgery at our institution were included. Chest CT, highly correlated with dual-energy X-ray absorptiometry (DXA), was used to analyze the baseline and preoperative T10, T12, and L1 BMD. We analyzed disease-free survival (DFS) and overall survival (OS) through Kaplan-Meier survival curves, cox regression, and restricted cubic splines (RCS) . Major pathologic response (MPR) and pathologic complete response (pCR) were compared through logistic regression. Subgroup analysis and sensitivity analysis were conducted to evaluate the accuracy of the results.  \nResults Median DFS was 22.58 months, and 14 patients experienced tumor recurrence or death. A significant decrease in BMD was observed at the T10, T12, and L1 vertebrae following NICT (p \u003C 0. 001) . Patients with higher baseline and preoperative L1 BMD had significantly improved DFS (p = 0 . 002, p = 0 . 002) . The prognostic value for BMD was confirmed through RCS analysis and multivariate Cox-regression analysis, as well as sensitivity analysis. Subgroup analysis revealed that the effect of L1 BMD on DFS showed significant interaction in age and MPR groups, suggesting age specific and treatment-response specific differences.  \n†Fengyi Zhou and Peile Li contributed equally to this work.  \n*Correspondence: Yazhuo Liu [3013801290@qq.com](3013801290@qq.com)[ ](3013801290@qq.com)Wenliang Liu [liuwenliang@csu.edu.cn](liuwenliang@csu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nZhou et al. World Journal of Surgical Oncology (2026) 24:69 Page 2 of 15  \nConclusion Both baseline and preoperative L1 BMD are valuable, readily available, and independent prognostic biomarkers for DFS in NSCLC patients receiving NICT.  \nHighlights  \nKey Findings  \n• Baseline and preoperative L1 bone mineral density (BMD","cbCaioFNwXWQinYt","https://ap.wps.com/l/cbCaioFNwXWQinYt","pdf",3057715,15,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Highlights\n# Introduction","[{\"question\":\"What is the main goal of the study on bone mineral density in NSCLC?\",\"answer\":\"To determine whether CT-derived bone mineral density (BMD) predicts prognosis, particularly disease-free survival (DFS), in NSCLC patients undergoing neoadjuvant chemoimmunotherapy (NICT).\"},{\"question\":\"How was BMD measured and which vertebrae were assessed?\",\"answer\":\"Baseline and preoperative BMD were analyzed from chest CT for T10, T12, and L1 vertebrae, with CT described as highly correlated with dual-energy X-ray absorptiometry (DXA).\"},{\"question\":\"What were the key prognostic findings for L1 BMD?\",\"answer\":\"Higher baseline and preoperative L1 BMD were associated with significantly improved DFS, and both measures were concluded to be valuable independent prognostic biomarkers.\"}]","Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy | PDF",1790099087,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8302db546ee31b05145ac8ac78a04c1f.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/827c271cb92b50ae6ce5609d6734cf60.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ed0bdffffe8e8dce4b9958011dfeb43.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30e5394a092e51dfbf7efc29e545c443.webp",980,1306]